Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(25%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
1
25%
Ph phase_2
2
50%

Phase Distribution

0

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(2)

Detailed Status

Completed2
Not yet recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (66.7%)
Phase 31 (33.3%)

Trials by Status

completed250%
not_yet_recruiting125%
recruiting125%

Recent Activity

1 active trials
Showing 4 of 4
recruitingphase_3

Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer

NCT07389265
not_yet_recruitingphase_2

ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer"

NCT07381764
completed

A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment

NCT01082315
completedphase_2

Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma

NCT00044863

Clinical Trials (4)

Showing 4 of 4 trials
NCT07389265Phase 3

Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer

Recruiting
NCT07381764Phase 2

ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer"

Not Yet Recruiting
NCT01082315

A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment

Completed
NCT00044863Phase 2

Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4